11 completed, 2 unknown, 2 withdrawn, 1 terminated. 16 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 11, Unknown 2, Withdrawn 2, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Methamphetamine Dependence: new trials by email Literature Review of Methamphetamine Dependence trials Research Report on Methamphetamine Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence Lisdexamfetamine, Placebo - Methamphetamine Dependence | Phase 1 | Completed | University of Arkansas | 19 | 2014-02-01 | 2017-08-22 |
| Buspirone as a Candidate Medication for Methamphetamine Abuse Methamphetamine, Placebo - Methamphetamine Dependence, Methamphetamine Abuse | Phase 1 | Completed | University of Kentucky | 9 | 2013-04-01 | 2018-02-07 |
| Clinical Efficacy of Atomoxetine for Methamphetamine Dependence Atomoxetine, placebo - Methamphetamine Dependence | Phase 1 / Phase 2 | Completed | University of Arkansas | 20 | 2012-04-01 | 2017-02-09 |
| A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence Text messages - Methamphetamine Dependence | Phase 1 | Completed | New Leaf Treatment Center | 25 | 2012-04-01 | 2013-07-10 |
| Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study placebo, Naltrexone and Bupropion SR - Methamphetamine Dependence | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 16 | 2011-08-01 | 2017-01-12 |
| Varenicline as a Treatment for Methamphetamine Dependence Placebo, Varenicline - Methamphetamine Dependence, Methamphetamine Abuse | Phase 1 | Completed | Baylor College of Medicine | 17 | 2011-01-01 | 2013-06-13 |
| NAC as a Potential Treatment for Methamphetamine Dependence Placebo, N-acetylcysteine - Methamphetamine Abuse, Methamphetamine Dependence | Phase 1 | Completed | Baylor College of Medicine | 10 | 2010-03-01 | 2012-07-27 |
| RTI-336 as a Treatment for Methamphetamine Dependence RTI-336, Placebo - Methamphetamine Dependence, Substance Abuse | Phase 1 | Withdrawn | Baylor College of Medicine | 2010-01-01 | 2012-05-18 | |
| Safety Assessment of Atomoxetine With MA IV Administration Atomoxetine, then Placebo, Placebo, then Atomoxetine - Methamphetamine Abuse, Methamphetamine Dependence | Phase 1 | Terminated | University of California, Los Angeles | 6 | 2009-10-01 | 2017-06-02 |
| Rivastigmine as a Treatment for Methamphetamine Dependence Placebo, Rivastigmine - Methamphetamine Dependence, Substance Abuse | Phase 1 | Completed | Baylor College of Medicine | 17 | 2009-07-01 | 2012-07-27 |
| An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Perindopril, Placebo, Candesartan - Methamphetamine Dependence, Methamphetamine Abuse | Phase 1 | Completed | Baylor College of Medicine | 80 | 2009-05-01 | 2022-04-26 |
| Open-Label Disulfiram for Methamphetamine Dependence Disulfiram - Methamphetamine Dependence | Phase 1 / Phase 2 | Completed | University of Arkansas | 15 | 2008-08-01 | 2012-02-27 |
| Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH) OROS-MPH - Methamphetamine Dependence, Methamphetamine Abuse | Phase 1 | Completed | University of Cincinnati | 16 | 2008-01-01 | 2017-01-12 |
| Varenicline-Methamphetamine Interaction Study (2008) Varenicline, Placebo - Methamphetamine Dependence, Substance Abuse | Phase 1 | Withdrawn | Baylor College of Medicine | 2008-01-01 | 2012-07-27 | |
| Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1 Lobeline - Methamphetamine Dependence | Phase 1 | Unknown | National Institute on Drug Abuse (NIDA) | 12 | 2006-02-01 | 2017-01-11 |
| Ph1 Lobeline Interaction Study - 1 Lobeline - Methamphetamine Dependence | Phase 1 | Unknown | National Institute on Drug Abuse (NIDA) | 10 | 2017-01-11 |
Substance-Related Disorders (8) · Behavior, Addictive (2) · Recurrence (1)
Chemically-Induced Disorders (8) · Mental Disorders (8) · Behavior (2) · Compulsive Behavior (2) · Impulsive Behavior (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Sugars (6) · Atomoxetine Hydrochloride (2) · Lobeline (2) · Varenicline (2) · 3beta-(4-chlorophenyl) tropane-2beta-(3-(4'-methylphenyl) isoxazol-5-yl) hydrochloride (1) · Acetylcysteine (1) · Disulfiram (1) · Lisdexamfetamine Dimesylate (1) · Methamphetamine (1) · Methylphenidate (1) · Naltrexone (1) · Perindopril (1) · Rivastigmine (1) · candesartan (1) · candesartan cilexetil (1)
Baylor College of Medicine (6) · National Institute on Drug Abuse (NIDA) (3) · University of Arkansas (3) · New Leaf Treatment Center (1) · University of California, Los Angeles (1) · University of Cincinnati (1) · University of Kentucky (1)
United States (14) · Canada (1)
Alison Oliveto, PhD (2) · Reese Jones, M.D. (2) · Richard De La Garza, II, PhD (2) · Edward Sellers, MD, PhD (1) · Eugene Somoza, MD, PhD (1) · Richard De La Garza, PhD (1) · S. Alex Stalcup, MD (1) · Steven Shoptaw, PhD (1) · Thomas F Newton, M.D. (1) · Thomas Newton, MD (1)
P50DA018185 (2), P50DA018197 (2), R01DA027134 (2), R01DA023468 (1), R01DA023964 (1), R21DA024756 (1), R21DA034824 (1), R21DA035481 (1)